Visit our news section for more articles.
News Our full Mednous news archive Appointments Latest industry appointments Events A list of upcoming industry events
Evernow Publishing Ltd Privacy Policy. Read more.
Subscribe to MedNous and get ahead in the business of medical innovation. Subscribe now.
The latest MedNous journal. Subscribe to download.
Switzerland
Novartis has moved aggressively to expand its cardiovascular portfolio with an agreed bid for The Medicines Company, valued at $9.7 billion. The US company’s lead product, inclisiran, is a small interfering RNA drug for the treatment of atherosclerotic cardiovascular disease and familial hypercholesterolemia. The Medicines Company expects to make regulatory submissions in the US before the end of 2019 and in Europe in the first quarter of 2020.
France
A French company that is working on antibody therapeutics for cancer indications has raised $53 million (€48 million) in a Series B round in order to take its lead product into the clinic. ImCheck Therapeutics SAS is developing a compound that targets a member of the butyrophilin family of checkpoint molecules and engages gamma delta T cells to fight cancer.
Germany
ViGeneron GmbH, a spin-out of the Ludwig-Maximilians-University in Munich, Germany, has closed a Series A funding round enabling it to advance two viral vector-based gene therapy platforms and develop two programmes for ophthalmic indications. The size of the funding was not disclosed. It was led by WuXi AppTec Group and Sequoia Capital of China.
Netherlands
Switzerland
United Kingdom
Switzerland
Germany
United States
Germany
Denmark
United States
Germany
Visit our news section for more articles.
News Our full Mednous news archive Appointments Latest industry appointments Events A list of upcoming industry events
© 2019 Evernow Publishing Ltd. Powered by Drupal.